[{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Undisclosed","graph2":"Phase I","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"6","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.98999999999999999,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.98999999999999999,"dosageForm":"Tablet, Delayed Release","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"11","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ASP015K","moa":"Janus Kinase (JAK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"6","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ASP015K","moa":"Janus Kinase (JAK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"6","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ASP015K","moa":"Janus Kinase (JAK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"6","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ASP015K","moa":"Janus Kinase (JAK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"6","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Cetrelimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":1.7,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Legend Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"JANSSEN BIOTECH","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Undisclosed","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Pharmacyclics","highestDevelopmentStatusID":"1","companyTruncated":"JANSSEN BIOTECH \/ Pharmacyclics"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Cellular Biomedicine Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Prizloncabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Lava Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Elektrofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0.79000000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.79000000000000004,"dosageForm":"Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Fate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":3.1000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":3.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Genocea","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Terence Friedlander, MD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Terence Friedlander, MD","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Terence Friedlander, MD"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Barry A. Boilson","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Undisclosed","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Barry A. Boilson","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Barry A. Boilson"}]
Find Clinical Drug Pipeline Developments & Deals by JANSSEN BIOTECH
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
